Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 10
2003 12
2004 6
2005 7
2006 5
2007 5
2008 12
2009 13
2010 11
2011 17
2012 16
2013 14
2014 14
2015 16
2016 21
2017 20
2018 22
2019 24
2020 27
2021 29
2022 24
2023 21
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Results by year

Filters applied: . Clear all
Page 1
O-glycan determinants regulate VWF trafficking to Weibel-Palade bodies.
Karampini E, Doherty D, Bürgisser PE, Garre M, Schoen I, Elliott S, Bierings R, O'Donnell JS. Karampini E, et al. Among authors: o donnell js. Blood Adv. 2024 Apr 19:bloodadvances.2023012499. doi: 10.1182/bloodadvances.2023012499. Online ahead of print. Blood Adv. 2024. PMID: 38640438
Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH.
Baker RI, Choi P, Curry N, Gebhart J, Gomez K, Henskens Y, Heubel-Moenen F, James P, Kadir RA, Kouides P, Lavin M, Lordkipanidze M, Lowe G, Mumford A, Mutch N, Nagler M, Othman M, Pabinger I, Sidonio R, Thomas W, O'Donnell JS; ISTH SSC Von Willebrand Factor, Platelet Physiology, and Women’s Health Issues in Thrombosis and Haemostasis. Baker RI, et al. Among authors: o donnell js. J Thromb Haemost. 2024 Mar 20:S1538-7836(24)00163-6. doi: 10.1016/j.jtha.2024.03.005. Online ahead of print. J Thromb Haemost. 2024. PMID: 38518896
Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies.
Atiq F, Blok R, van Kwawegen CB, Doherty D, Lavin M, van der Bom JG, O'Connell NM, de Meris J, Ryan K, Schols SEM, Byrne M, Heubel-Moenen FCJI, van Galen KPM, Preston RJS, Cnossen MH, Fijnvandraat K, Baker RI, Meijer K, James P, Di Paola J, Eikenboom J, Leebeek FWG, O'Donnell JS. Atiq F, et al. Among authors: o donnell js. Blood. 2024 Apr 4;143(14):1414-1424. doi: 10.1182/blood.2023022457. Blood. 2024. PMID: 38142407 Free PMC article.
Glycolytic reprogramming fuels myeloid cell-driven hypercoagulability.
Rehill AM, Leon G, McCluskey S, Schoen I, Hernandez-Santana Y, Annett S, Klavina P, Robson T, Curtis AM, Renné T, Hussey S, O'Donnell JS, Walsh PT, Preston RJS. Rehill AM, et al. Among authors: o donnell js. J Thromb Haemost. 2024 Feb;22(2):394-409. doi: 10.1016/j.jtha.2023.10.006. Epub 2023 Oct 20. J Thromb Haemost. 2024. PMID: 37865288 Free article.
The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A.
Valke LLFG, Verhagen MJA, Mulders BTPM, Polenewen R, Blijlevens NMA, Jansen JH, Mansouritorghabeh H, Elsheikh E, Reipert BM, Turecek PL, O'Donnell JS, Rijpma SR, Schols SEM, van Heerde WL, Meijer D. Valke LLFG, et al. Among authors: o donnell js. Thromb Res. 2023 Nov;231:112-120. doi: 10.1016/j.thromres.2023.10.007. Epub 2023 Oct 11. Thromb Res. 2023. PMID: 37844518
VWF-ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion.
Fogarty H, Ahmad A, Atiq F, Doherty D, Ward S, Karampini E, Rehill A, Leon G, Byrne C, Geoghegan R, Conroy H, Byrne M, Budde U, Schneppenheim S, Sheehan C, Ngwenya N, Baker RI, Preston RJS, Tuohy E, McMahon C, O'Donnell JS. Fogarty H, et al. Among authors: o donnell js. Blood Adv. 2023 Nov 28;7(22):6974-6989. doi: 10.1182/bloodadvances.2023010824. Blood Adv. 2023. PMID: 37773926 Free PMC article.
Publisher Correction: Dimethyl fumarate and 4-octyl itaconate are anticoagulants that suppress Tissue Factor in macrophages via inhibition of Type I Interferon.
Ryan TAJ, Hooftman A, Rehill AM, Johansen MD, O' Brien EC, Toller-Kawahisa JE, Wilk MM, Day EA, Weiss HJ, Sarvari P, Vozza EG, Schramm F, Peace CG, Zotta A, Miemczyk S, Nalkurthi C, Hansbro NG, McManus G, O'Doherty L, Gargan S, Long A, Dunne J, Cheallaigh CN, Conlon N, Carty M, Fallon PG, Mills KHG, Creagh EM, O' Donnell JS, Hertzog PJ, Hansbro PM, McLoughlin RM, Wygrecka M, Preston RJS, Zasłona Z, O'Neill LAJ. Ryan TAJ, et al. Among authors: o donnell js. Nat Commun. 2023 Jul 20;14(1):4374. doi: 10.1038/s41467-023-40034-1. Nat Commun. 2023. PMID: 37474527 Free PMC article. No abstract available.
312 results